Efficacy of SN132D in Patients With Suspected Endometriosis

Endometriosis Clinical Trial

Official title:

A Phase IIa, Single Centre, Open Label, Proof of Concept Study Concerning Efficacy of the Novel Intravenous Contrast Agent SN132D in Patients With Suspected Endometriosis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05664828
• Other study ID #: SPAGOPIX-02
• Secondary ID: 2022-000652-11
• Status: Completed
• Phase: Phase 2
• Start date: November 17, 2022
• Est. completion date: September 12, 2023

Study information

• Verified date: December 2022
• Source: Spago Nanomedical AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase IIa, open-label, non-randomised and non-placebo-controlled study. The study is designed to evaluate the diagnostic value and safety of a single intravenous dose of SN132D in up to 18 participants with suspected endometriosis. Magnetic resonance imaging (MRI) will be performed pre- and post-infusion of SN132D.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: September 12, 2023
• Est. primary completion date: June 20, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent including willingness to undertake 3 MRI investigations in one day.

2. Females with endometriosis or suspected endometrial lesions at transvaginal ultrasound examination.

3. At least 18 years of age when signing the informed consent.

4. Adequate renal and hepatic function:

eGFR = 50 mL/min/1.73 m2, bilirubin <1 x upper limit of normal (ULN), creatinine <1 x ULN, ASAT and ALAT < 1 x ULN, Bilirubin ULN: 25 µmol/L, creatinine ULN: 90 µmol/L, ASAT ULN: 0.60 µkat/L and ALAT ULN: 0.75 µkat/L) at the screening visit.

5. Females of child-bearing potential* must agree to the use of effective contraception** or practice abstinence during the study and for 30 days after the IMP administration.

*A female of child-bearing potential is a sexually mature female who 1) has not undergone a hysterectomy or bilateral oophorectomy, or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e. had had menses at any time in the preceding 24 consecutive months).

**Effective contraception is defined as contraceptive methods with a failure rate of < 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD]or intrauterine hormone-releasing system [IUS]).

6. Adequate haematological function: haemoglobin (Hb) =90 g/L, absolute neutrophil count (ANC) =1.3x109 /L and platelet count = 100 x 109 /L.

Exclusion Criteria:

1. Female participants who are pregnant or who are currently breast feeding.

2. Conditions contraindicating MRI including, but not limited to, BMI > 40 kg/m2 at screening claustrophobia, metallic implants or internal electrical devices (e.g., cochlear implant, nerve stimulator, gastric pacemaker, bladder stimulator, pacemaker, defibrillator, artificial valves in heart, aneurysm clips, etc.), and permanent makeup or tattoos which in the Investigator's opinion might jeopardise the patient's safety or interfere with the imaging measurements. The Investigator is encouraged to contact the MR clinic for advice on which implants, tattoos, etc may be unsuitable.

3. Moderate to severe hypertension as judged by the Investigator.

4. History of significant cardiovascular disease such as myocardial infarction, congestive heart failure, stroke, serious cardiac arrhythmias, history of angina within 6 months prior to screening.

5. Clinically diagnosed obstruction of bile duct as judged by the Investigator.

6. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) which, in the opinion of the Investigator is clinically relevant, or will interfere with the ECG analysis.

7. Abnormalities detected during examination at screening and admission, which in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study.

8. Active infection requiring systemic treatment within one week prior to agent administration.

9. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study.

10. Known human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment. Participants with chronic HBV or HCV infection are eligible at the Investigator's discretion provided that the disease is stable and sufficiently controlled under treatment.

11. Any use of alcohol within 24 hours of admission to the clinic.

12. Plasma donation within 1 month of screening or any blood donation or corresponding blood loss during 3 months prior to screening.

13. Use of investigational agent within four weeks before Visit 1 or plans to initiate treatment with an investigational agent during the study.

Related Conditions & MeSH terms

• Endometriosis

Intervention

Drug:
• SN132D
Manganese-based macromolecular MRI contrast agent

Locations

Country	Name	City	State
Sweden	Kvinnokliniken, Skåne University Hospital	Malmö	Skåne

Sponsors (1)

Lead Sponsor	Collaborator
Spago Nanomedical AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MRI enhancing effect	MRI enhancing effect will be evaluated by assessing changes between pre-dose images and post-dose images acquired using longitudinal relaxation time (T1)-weighted imaging sequences, analysing contrast-to-noise in endometriosis lesions vs reference tissue, signal-to-noise in endometriosis lesions. Additional MR-scan characteristic parameters may be calculated if deemed appropriate.	Day 1
Secondary	Diagnostic Value Evaluation for endometriosis lesions.	Compare the number, size and site of endometriosis lesions obtained by SN132D imaging to transvaginal ultrasound (TUS) and clinically used non-contrast MRI	Day 1
Secondary	Diagnostic Value Evaluation for deep pelvic endometriosis lesions.	Compare the number, size and site of deep pelvic endometriosis lesionsobtained by SN132D imaging to transvaginal ultrasound (TUS) and clinically used non-contrast MRI	Day 1
Secondary	Number of treatments related adverse events (AEs)		Day 1 up to 2 weeks